Key result
Galectin-3 drives atherosclerosis and heart failure pathogenesis, serving as a potential prognostic and therapeutic target.
Answers are grounded in this paper and cite their sources.
Galectin-3 (Gal-3) is a β-galactoside-binding protein belonging to the lectin family with pleiotropic regulatory activities and several physiological cellular functions, such as cellular growth, proliferation, apoptosis, differentiation, cellular adhesion, and tissue repair. Inflammation, tissue fibrosis and angiogenesis are the main processes in which Gal-3 is involved. It is implicated in the pathogenesis of several diseases, including organ fibrosis, chronic inflammation, cancer, atherosclerosis and other cardiovascular diseases (CVDs). This review aims to explore the connections of Gal-3 with cardiovascular diseases since they represent a major cause of morbidity and mortality. We herein discuss the evidence on the pro-inflammatory role of Gal-3 in the atherogenic process as well as the association with plaque features linked to lesion stability. We report the biological role and molecular mechanisms of Gal-3 in other CVDs, highlighting its involvement in the development of cardiac fibrosis and impaired myocardium remodelling, resulting in heart failure and atrial fibrillation. The role of Gal-3 as a prognostic marker of heart failure is described together with possible diagnostic applications to other CVDs. Finally, we report the tentative use of Gal-3 inhibition as a therapeutic approach to prevent cardiac inflammation and fibrosis.
No takes yet. Share an insight, caveat, or question.
Blanda et al. (2020) conducted a review in Cardiovascular diseases. Galectin-3 was evaluated. Galectin-3 is implicated in the pathogenesis of cardiovascular diseases such as atherosclerosis and heart failure, and may serve as a prognostic marker and therapeutic target.
Synapse has enriched 10 related papers. Consider them for comparative context: